Phase II study of oral topotecan plus bevacizumab (topo-bev) for second-line treatment of small cell lung cancer (SCLC)

被引：2
|
作者：
Waterhouse, D. M.
Morgan, S. K.
Spigel, D. R.
Shankar, S.
Dharan, B.
Foose, D. E.
Bhatt, K.
机构：
[1] Oncol Hematol Care Inc, Cincinnati, OH USA
[2] Florida Canc Specialists, Naples, FL USA
[3] Sarah Cannon Res Inst Tennessee Oncol, Nashville, TN USA
[4] GlaxoSmithKline, Collegeville, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.7055
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7055
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Randomized phase III trial of amrubicin versus topotecan (Topo) as second-line treatment for small cell lung cancer (SCLC).
    Jotte, R.
    Von Pawel, J.
    Spigel, D. R.
    Socinski, M. A.
    O'Brien, M.
    Paschold, E. H.
    Mezger, J.
    Steins, M.
    Bosquee, L.
    Bubis, J. A.
    Nackaerts, K.
    Perez, J. M. Trigo
    Clingan, P. R.
    Schuette, W.
    Lorigan, P.
    Reck, M.
    Domine, M.
    Shepherd, F. A.
    McNally, R.
    Renschler, M. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [2] Randomized phase 3 trial of amrubicin versus topotecan as second-line treatment for small cell lung cancer (SCLC)
    von Pawel, J.
    Jotte, R.
    Spigel, D. R.
    Socinski, M. A.
    O'brien, M. E. R.
    Pashold, E. H.
    Mezger, J.
    Steins, M.
    Bosquee, L.
    Bubis, J.
    Nackaerts, K.
    Trigo, J. M.
    Clingan, P.
    Schuette, W.
    Lorigan, P. C.
    Reck, M.
    Domine, M.
    Shepard, F. A.
    Mcnally, R.
    Renschler, M. F.
    ONKOLOGIE, 2011, 34 : 122 - 124
  • [3] Phase I study of the topotecan and epirubicin combination as second line treatment in small cell lung cancer (SCLC).
    Mavroudis, D
    Rapti, A
    Ardavanis, G
    Kouroussis, C
    Kakolyris, S
    Kalbakis, K
    Vardakis, N
    Vamvakas, L
    Klapsinos, N
    Georgoulias, V
    ANNALS OF ONCOLOGY, 2000, 11 : 120 - 120
  • [4] A phase II study of second-line bendamustine in relapsed or refractory small cell lung cancer (SCLC)
    Lovly, Christine Marie
    Li, Chung-I
    Hutchison, Anne Smith
    Carbone, David Paul
    Johnson, David H.
    Keedy, Vicki Leigh
    Pao, William
    Sandler, Alan
    Horn, Leora
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [5] A phase II study of second-line bendamustine in relapsed or refractory small cell lung cancer (SCLC)
    Venepalli, N. K.
    Hutchison, A. S.
    Carbone, D. P.
    Johnson, D. H.
    Keedy, V. L.
    Pao, W.
    Sandler, A.
    Horn, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [6] Topotecan plus Epirubicin as a second line chemotherapy in Small Cell Lung Cancer: A phase II study
    Charpidou, Andriani G.
    Chondrou, Evangelia
    Tsimpoukis, Sotirios
    Kotteas, Elias
    Tourkantonis, Ioannis
    Demertzis, Panos
    Papaetis, George
    Syrigos, Kostas N.
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S811 - S811
  • [7] Topotecan effective for second-line treatment of small cell lung cancer
    不详
    IRISH MEDICAL JOURNAL, 1997, 90 (05) : 198 - 198
  • [8] A randomized phase II trial of oral topotecan versus docetaxel in the second-line treatment of non-small-cell lung cancer
    Jones, Suzanne
    Thompson, Dana
    Barton, John
    Patton, Jeff
    Shipley, Dianna
    Greco, E. Anthony
    Spigel, David
    Infante, Jeff
    Burris, Howard A., III
    CLINICAL LUNG CANCER, 2008, 9 (03) : 154 - 159
  • [9] The role of topotecan in treating small cell lung cancer: second-line treatment
    von Pawel, J
    LUNG CANCER, 2003, 41 : S3 - S8
  • [10] Pooled analysis of topotecan (T) in the second-line treatment of patients (pts) with sensitive small cell lung cancer (SCLC)
    Eckardt, J
    Depierre, A
    Ardizzoni, A
    VonPawel, J
    Fields, S
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 1041 - 1041
12345